Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
Last trade$0.4419
Day change-$0.0581 (-11.62%)
Day range$0.43 – $0.526
Volume1,810,408
Market cap$18M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$18.38M
Price / earnings
—
Price / book
0.42×
Price / sales
—
EV / sales
—
EV / EBITDA
0.84×
Profitability
Earnings per share
-$0.68
Return on assets
-53.42%
Return on equity
-56.78%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
15.67×
Quick ratio
15.67×
Cash ratio
14.96×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$19.38M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for KTTA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.51M
$2.03M
$1.93M
$7.51M
$1.75M
$1.66M
$1.95M
$1.75M
Research and development
$4.46M
$3.69M
$2.94M
$2.74M
$1.36M
$2.15M
$1.73M
$1.51M
Total operating expenses
$6.97M
$5.71M
$4.88M
$10.26M
$3.11M
$3.81M
$3.68M
$3.26M
Operating income
-$6.97M
-$5.71M
-$4.88M
-$10.26M
-$3.11M
-$3.81M
-$3.68M
-$3.26M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$6.58M
-$5.27M
-$2.87M
-$10.11M
-$3.04M
-$3.72M
-$3.56M
-$3.18M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$6.58M
-$5.27M
-$2.87M
-$10.11M
-$3.04M
-$3.72M
-$3.56M
-$3.18M
Net income attributable to common shareholders
-$6.58M
-$5.27M
-$2.87M
-$10.11M
-$3.04M
-$3.72M
-$3.56M
-$3.18M
EBITDA
-$6.5M
-$5.87M
-$4.72M
-$10.1M
-$2.61M
-$3.96M
-$3.52M
-$3.1M
Basic earnings per share
-$0.20
-$0.16
-$0.12
-$0.79
-$0.41
-$0.66
-$1.61
-$2.53
Diluted earnings per share
-$0.20
-$0.16
-$0.12
-$0.79
-$0.41
-$0.66
-$1.61
-$2.53
Recent news
Company coverage with links to the original publishers.
Pasithea Therapeutics announced positive Phase 1/1b clinical data for PAS-004, its oral MEK inhibitor candidate, showing substantial reductions in cutaneous neurofibroma size (median 41-46% reduction) and early activity in plexiform neurofibromas across all participants. The drug demonstrated a favorable safety profile with no serious adverse events or treatment-related discontinuations. The FDA has cleared the IND for a Phase 2 randomized, placebo-controlled trial in approximately 200 adults with NF1-associated cutaneous neurofibromas.
THEA, a predictive behavioral AI network focused on risk markets, announced $8 million in financing led by Maven11 Capital. However, the article begins with a retraction notice advising readers to disregard the original news release, creating significant uncertainty about the announcement's validity.
Pasithea Therapeutics raised $60 million through a public offering of 80 million shares at $0.75 per share, led by healthcare investors. The proceeds will support ongoing research and extend the company's cash runway through the first half of 2028.
Pasithea Therapeutics reported positive pharmacokinetic data for its PAS-004 tablet in a Phase 1/1b trial for neurofibromatosis type 1 (NF1) patients, demonstrating linear dose-proportionality and improved tablet formulation characteristics.
The neurofibromatosis type 1 market is expected to grow significantly due to advances in treatment, increased diagnoses, and ongoing clinical trials. Unmet needs in adult populations and systemic disease management create opportunities for new entrants and differentiated strategies.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.